Illumina to Divest MCED Test Provider GRAIL: FTC

The Federal Trade Commission (FTC) has issued an order mandating Illumina, a leading producer of next-generation sequencing platforms, to divest GRAIL, which provides a Multi-Cancer Early Detection test (MCED). The next-generation sequencing platforms are used in analyzing genetic material from blood samples for MCED tests. According to the FTC, this acquisition would have a negative effect on prices, options and competition for MCED tests in the United States.